Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma.

EMBO molecular medicine - 7 Dec 2022

Paris Anaïs, Tardif Nina, Baietti Francesca M, Berra Cyrille, Leclair Héloïse M, Leucci Eleonora, Galibert Marie-Dominique, Corre Sébastien

Abstract excerpt

The nongenetic mechanisms required to control tumor phenotypic plasticity and shape drug-resistance remain unclear. We show here that the Aryl hydrocarbon Receptor (AhR) transcription factor directly regulates the gene expression program associated with the acquisition of resistance to BRAF inhibitor (BRAFi) in melanoma. In addition, we show in melanoma cells that canonical activation of AhR mediates the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Computational Drug Discovery Methods

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dasatinib

Share to Melanoma

Share to Melanoma and MAPK Pathways

Share to Phenotype

Share to Protein Kinase Inhibitors

Share to Receptors, Aryl Hydrocarbon

Source

Open in PubMed Open full text

Identifiers

PMID: 36305167
DOI: 10.15252/emmm.202215677
PMCID: PMC9728058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma.PMID 36305167Read ↗

Androgen Receptor is a Determinant of Melanoma targeted drug resistanceSemantic proximity Read ↗

Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer.Semantic proximity Read ↗

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary ConvergenceSemantic proximity Read ↗

Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapySemantic proximity Read ↗

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.Semantic proximity Read ↗

Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?Semantic proximity Read ↗

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity Read ↗

Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1RSemantic proximity Read ↗

Androgen receptor-dependent DRAM1 activation drives autophagic resistance to BRAF inhibitors in BRAFV600-mutant melanoma.Semantic proximity Read ↗

Adaptive resistance to <scp>RAF</scp> inhibitors in melanomaSemantic proximity Read ↗

YAP1 drives aggressive and therapy resistant state in melanoma through reprogramming the chromatin and regulating immune evasive programsSemantic proximity Read ↗

CRISPR Screens Identify Essential Cell Growth Mediators in BRAF-inhibitor Resistant MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.